Suchergebnisse - "Van Schalkwyk, Marije"

PubPharm (29)

1

Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection

enthalten in: The lancet. Gastroenterology & hepatology | 2024

von Delphin, M. | Mohammed, K. | Downs, L. | +13

2

Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum : results from IMPAACT P1026s

enthalten in: Antimicrobial agents and chemotherapy | 2023

von Van Schalkwyk, M. | Bekker, A. | Decloedt, E. | +18

3

Perspectives of people living with HIV and health workers about a point-of-care adherence assay : a qualitative study on acceptability

enthalten in: AIDS care | 2023

von Mcinziba, A. | Wademan, D. | Viljoen, L. | +8

4

Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis

enthalten in: Pharmacogenetics and genomics | 2023

von Agyemang, N. | Scarsi, K. | Baker, P. | +20

5

Barriers that prevent adults living with HBV infection from participating in clinical research : experience from South Africa

enthalten in: Journal of virus eradication | 2023

von Mofokeng, N. | Maponga, T. | van Schalkwyk, M. | +15

6

Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens

enthalten in: AIDS (London, England) | 2022

von van Zyl, G. | Jennings, L. | Kellermann, T. | +7

7

Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings

enthalten in: AIDS research and human retroviruses | 2022

von Jennings, L. | Kellermann, T. | Spinelli, M. | +7

8

Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings : ACTG A5288 strategy trial

enthalten in: Journal of the International AIDS Society | 2022

von Avihingsanon, A. | Hughes, M. | Salata, R. | +31

9

A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]) : a phase 4, open-label, single-arm trial

enthalten in: The lancet. Gastroenterology & hepatology | 2022

von Solomon, S. | Wagner-Cardoso, S. | Smeaton, L. | +22

10

Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings : ACTG A5288 strategy trial

enthalten in: Journal of the International AIDS Society | 2022

von Avihingsanon, A. | Hughes, M. | Salata, R. | +30